NIH Weekly Funding Opportunities and Policy Notices
Population Dynamics Centers Research Infrastructure Program FY 2021 (P2C Clinical Trial Not Allowed)
Funding Opportunity RFA-HD-21-010 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.
Notice NOT-AG-20-017 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-20-006 from the NIH Guide for Grants and Contracts. This FOA encourages applications from institutions that propose to establish research experiences in kidney technology development. Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. The intent of this FOA is to recruit undergraduate students as participants and to engage students from engineering and technical domains, but applicants may also propose the inclusion of medical students, graduate students and/or dual-degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.
Notice NOT-NS-20-042 from the NIH Guide for Grants and Contracts
Notice NOT-CA-20-031 from the NIH Guide for Grants and Contracts
Notice NOT-TR-20-008 from the NIH Guide for Grants and Contracts
Notice NOT-ES-20-013 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-083 from the NIH Guide for Grants and Contracts
Notice NOT-OD-20-077 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-20-135 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Guide Notices will be routed directly to the NIH awarding component signed on to the Emergency Guide Notice. Only applications submitted in response to an Emergency Guide Notice published by an Institute or Center (IC) will be allowed to apply to this Funding Opportunity Announcement.
Notice NOT-OD-20-082 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AR-21-004 from the NIH Guide for Grants and Contracts. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for rheumatic diseases research areas within its mission. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on rheumatic diseases, enabling them to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively, with the broad overall goal of accelerating, enriching, and enhancing the effectiveness of ongoing basic, translational, and clinical research and promoting new research within the NIAMS mission.
Notice NOT-NS-20-040 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-20-015 from the NIH Guide for Grants and Contracts. The objective of this Funding Opportunity Announcement (FOA) is to pair Bioengineers and Immunologists to leverage emerging innovative knowledge in physical and computational science for the design and development of an HIV-1 vaccine.
Funding Opportunity RFA-AI-20-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support basic, translational, and clinical research to improve the understanding of the effector or immunoregulatory potentials of NK cells for HIV prevention, control and/or eradication.
Funding Opportunity RFA-CA-20-033 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.
Funding Opportunity RFA-AI-20-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.
Funding Opportunity PAS-20-121 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV.
Notice NOT-HL-20-753 from the NIH Guide for Grants and Contracts
Notice NOT-DC-20-002 from the NIH Guide for Grants and Contracts